Axsome Therapeutics's Return On Capital Employed Overview
Portfolio Pulse from Benzinga Insights
Axsome Therapeutics (NASDAQ:AXSM) reported Q1 sales of $94.58 million, up 81.68%, but still posted a loss of $11.22 million. The company's Return on Capital Employed (ROCE) for Q1 was -0.1%, suggesting inefficient capital allocation.
May 22, 2023 | 2:53 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Axsome Therapeutics reported an 81.68% increase in Q1 sales but still posted a loss. The company's Q1 ROCE of -0.1% suggests inefficient capital allocation.
Axsome Therapeutics reported an increase in sales but still posted a loss, which could negatively impact the stock price. Additionally, the negative ROCE of -0.1% indicates that the company may not be effectively allocating its capital, which could lead to unfavorable long-term returns and affect the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100